L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type: Results of a 15–Month Trial

W. J. Burke, W. H. Roccaforte, Steven Phillip Wengel, B. L. Bayer, A. E. Ranno, N. K. Willcockson

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Objective: To examine the cognitive and behavioral effects of L‐deprenyl in persons with mild dementia of the Alzheimer type (DAT) over a 15‐month period. Design: A 15‐month randomized, double‐blind, placebo‐controlled trial using a parallel‐group design. Participants: 39 subjects with mild DAT (CDR 1) selected using NINCDS‐ADRDA criteria. Outcome Measures: A battery of neuropsychological tests and clinical rating scales. Results: The placebo and L‐deprenyl subjects were similar at baseline on the clinical and neuropsychological tests. The total score on the Brief Psychiatric Rating Scale (BPRS) was significantly less after 15 months in subjects taking L‐deprenyl. The only individual item of the BPRS which differed between groups was disorientation. There was no evidence of a L‐deprenyl effect on any other clinical or neuropsychological measure after 2, 8, or 15 months. Conclusion: L‐deprenyl did appear to have a slight effect on a single measure of psychopathology, the BPRS. It did not have a measurable impact on any other measure of behavior or cognitive function over a 15‐month period in this group of subjects with mild DAT and did not appear to slow the progression of the disease. 1993 The American Geriatrics Society

Original languageEnglish (US)
Pages (from-to)1219-1225
Number of pages7
JournalJournal of the American Geriatrics Society
Volume41
Issue number11
DOIs
StatePublished - Nov 1993

Fingerprint

Brief Psychiatric Rating Scale
Alzheimer Disease
Neuropsychological Tests
Confusion
Psychopathology
Cognition
Disease Progression
Therapeutics
Placebos
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type : Results of a 15–Month Trial. / Burke, W. J.; Roccaforte, W. H.; Wengel, Steven Phillip; Bayer, B. L.; Ranno, A. E.; Willcockson, N. K.

In: Journal of the American Geriatrics Society, Vol. 41, No. 11, 11.1993, p. 1219-1225.

Research output: Contribution to journalArticle

Burke, W. J. ; Roccaforte, W. H. ; Wengel, Steven Phillip ; Bayer, B. L. ; Ranno, A. E. ; Willcockson, N. K. / L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type : Results of a 15–Month Trial. In: Journal of the American Geriatrics Society. 1993 ; Vol. 41, No. 11. pp. 1219-1225.
@article{3e07d6ea30a7474d9ef647c8b85ba4af,
title = "L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type: Results of a 15–Month Trial",
abstract = "Objective: To examine the cognitive and behavioral effects of L‐deprenyl in persons with mild dementia of the Alzheimer type (DAT) over a 15‐month period. Design: A 15‐month randomized, double‐blind, placebo‐controlled trial using a parallel‐group design. Participants: 39 subjects with mild DAT (CDR 1) selected using NINCDS‐ADRDA criteria. Outcome Measures: A battery of neuropsychological tests and clinical rating scales. Results: The placebo and L‐deprenyl subjects were similar at baseline on the clinical and neuropsychological tests. The total score on the Brief Psychiatric Rating Scale (BPRS) was significantly less after 15 months in subjects taking L‐deprenyl. The only individual item of the BPRS which differed between groups was disorientation. There was no evidence of a L‐deprenyl effect on any other clinical or neuropsychological measure after 2, 8, or 15 months. Conclusion: L‐deprenyl did appear to have a slight effect on a single measure of psychopathology, the BPRS. It did not have a measurable impact on any other measure of behavior or cognitive function over a 15‐month period in this group of subjects with mild DAT and did not appear to slow the progression of the disease. 1993 The American Geriatrics Society",
author = "Burke, {W. J.} and Roccaforte, {W. H.} and Wengel, {Steven Phillip} and Bayer, {B. L.} and Ranno, {A. E.} and Willcockson, {N. K.}",
year = "1993",
month = "11",
doi = "10.1111/j.1532-5415.1993.tb07306.x",
language = "English (US)",
volume = "41",
pages = "1219--1225",
journal = "Journal of the American Geriatrics Society",
issn = "0002-8614",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type

T2 - Results of a 15–Month Trial

AU - Burke, W. J.

AU - Roccaforte, W. H.

AU - Wengel, Steven Phillip

AU - Bayer, B. L.

AU - Ranno, A. E.

AU - Willcockson, N. K.

PY - 1993/11

Y1 - 1993/11

N2 - Objective: To examine the cognitive and behavioral effects of L‐deprenyl in persons with mild dementia of the Alzheimer type (DAT) over a 15‐month period. Design: A 15‐month randomized, double‐blind, placebo‐controlled trial using a parallel‐group design. Participants: 39 subjects with mild DAT (CDR 1) selected using NINCDS‐ADRDA criteria. Outcome Measures: A battery of neuropsychological tests and clinical rating scales. Results: The placebo and L‐deprenyl subjects were similar at baseline on the clinical and neuropsychological tests. The total score on the Brief Psychiatric Rating Scale (BPRS) was significantly less after 15 months in subjects taking L‐deprenyl. The only individual item of the BPRS which differed between groups was disorientation. There was no evidence of a L‐deprenyl effect on any other clinical or neuropsychological measure after 2, 8, or 15 months. Conclusion: L‐deprenyl did appear to have a slight effect on a single measure of psychopathology, the BPRS. It did not have a measurable impact on any other measure of behavior or cognitive function over a 15‐month period in this group of subjects with mild DAT and did not appear to slow the progression of the disease. 1993 The American Geriatrics Society

AB - Objective: To examine the cognitive and behavioral effects of L‐deprenyl in persons with mild dementia of the Alzheimer type (DAT) over a 15‐month period. Design: A 15‐month randomized, double‐blind, placebo‐controlled trial using a parallel‐group design. Participants: 39 subjects with mild DAT (CDR 1) selected using NINCDS‐ADRDA criteria. Outcome Measures: A battery of neuropsychological tests and clinical rating scales. Results: The placebo and L‐deprenyl subjects were similar at baseline on the clinical and neuropsychological tests. The total score on the Brief Psychiatric Rating Scale (BPRS) was significantly less after 15 months in subjects taking L‐deprenyl. The only individual item of the BPRS which differed between groups was disorientation. There was no evidence of a L‐deprenyl effect on any other clinical or neuropsychological measure after 2, 8, or 15 months. Conclusion: L‐deprenyl did appear to have a slight effect on a single measure of psychopathology, the BPRS. It did not have a measurable impact on any other measure of behavior or cognitive function over a 15‐month period in this group of subjects with mild DAT and did not appear to slow the progression of the disease. 1993 The American Geriatrics Society

UR - http://www.scopus.com/inward/record.url?scp=0027443398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027443398&partnerID=8YFLogxK

U2 - 10.1111/j.1532-5415.1993.tb07306.x

DO - 10.1111/j.1532-5415.1993.tb07306.x

M3 - Article

C2 - 8227897

AN - SCOPUS:0027443398

VL - 41

SP - 1219

EP - 1225

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

SN - 0002-8614

IS - 11

ER -